Psyence Biomedical (PBM) Competitors $2.36 -2.67 (-53.08%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.98 +1.63 (+68.86%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBM vs. BCAB, CMMB, FNCH, CASI, ABP, SYBX, PRPH, LPCN, BLRX, and ATNFShould you be buying Psyence Biomedical stock or one of its competitors? The main competitors of Psyence Biomedical include BioAtla (BCAB), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH), CASI Pharmaceuticals (CASI), Abpro (ABP), Synlogic (SYBX), ProPhase Labs (PRPH), Lipocine (LPCN), BioLineRx (BLRX), and 180 Life Sciences (ATNF). These companies are all part of the "pharmaceutical products" industry. Psyence Biomedical vs. Its Competitors BioAtla Chemomab Therapeutics Finch Therapeutics Group CASI Pharmaceuticals Abpro Synlogic ProPhase Labs Lipocine BioLineRx 180 Life Sciences BioAtla (NASDAQ:BCAB) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends. Does the media favor BCAB or PBM? In the previous week, Psyence Biomedical had 7 more articles in the media than BioAtla. MarketBeat recorded 8 mentions for Psyence Biomedical and 1 mentions for BioAtla. BioAtla's average media sentiment score of 0.92 beat Psyence Biomedical's score of 0.25 indicating that BioAtla is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Psyence Biomedical 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, BCAB or PBM? BioAtla has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Do analysts recommend BCAB or PBM? BioAtla presently has a consensus target price of $5.00, suggesting a potential upside of 1,415.15%. Given BioAtla's stronger consensus rating and higher probable upside, research analysts clearly believe BioAtla is more favorable than Psyence Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Psyence Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in BCAB or PBM? 77.2% of BioAtla shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 11.5% of BioAtla shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation & earnings, BCAB or PBM? Psyence Biomedical has lower revenue, but higher earnings than BioAtla. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M1.75-$69.78M-$1.22-0.27Psyence BiomedicalN/AN/A$1.01MN/AN/A Is BCAB or PBM more profitable? Psyence Biomedical's return on equity of 0.00% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -373.47% -116.55% Psyence Biomedical N/A N/A N/A SummaryBioAtla beats Psyence Biomedical on 7 of the 12 factors compared between the two stocks. Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBM vs. The Competition Export to ExcelMetricPsyence BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.34M$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.13%P/E RatioN/A17.8528.9923.79Price / SalesN/A309.13440.5196.33Price / Cash1.3241.6335.0756.59Price / Book0.208.488.255.54Net Income$1.01M-$55.06M$3.25B$259.97M7 Day Performance-79.48%-3.99%-3.75%-4.67%1 Month Performance-56.14%8.53%2.99%3.29%1 Year Performance-99.28%6.51%25.34%17.92% Psyence Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBMPsyence Biomedical1.5284 of 5 stars$2.36-53.1%N/A-99.3%$1.34MN/A0.00N/ANews CoverageGap DownBCABBioAtla2.0604 of 5 stars$0.35-1.8%$5.00+1,338.4%-79.2%$20.68M$11M-0.2860Upcoming EarningsCMMBChemomab Therapeutics2.9277 of 5 stars$1.09flat$8.50+679.8%-1.4%$20.55MN/A-1.4320Positive NewsFNCHFinch Therapeutics GroupN/A$12.50-0.4%N/A+523.5%$20.08MN/A-1.42190Gap UpCASICASI Pharmaceuticals3.9495 of 5 stars$1.52-6.2%$4.00+163.2%-80.6%$19.92M$31.37M-0.60180Positive NewsGap UpABPAbproN/A$0.32+1.2%$4.00+1,136.9%N/A$19.42M$180K0.0015Gap DownSYBXSynlogic1.0258 of 5 stars$1.54-4.9%N/A-8.1%$18.95M$10K-0.6180Upcoming EarningsPRPHProPhase Labs0.6148 of 5 stars$0.35-21.1%N/A-88.8%$18.44M$5.85M-0.28130Gap DownHigh Trading VolumeLPCNLipocine2.6139 of 5 stars$3.27-3.8%$9.00+175.2%-36.5%$18.18M$11.20M-3.2110Positive NewsUpcoming EarningsBLRXBioLineRx2.0774 of 5 stars$4.13-0.7%$26.00+529.5%-85.7%$17.73M$22.34M-0.4740Gap DownATNF180 Life Sciences0.6124 of 5 stars$3.22+10.7%N/A+89.3%$17.57MN/A-0.217News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies BioAtla Alternatives Chemomab Therapeutics Alternatives Finch Therapeutics Group Alternatives CASI Pharmaceuticals Alternatives Abpro Alternatives Synlogic Alternatives ProPhase Labs Alternatives Lipocine Alternatives BioLineRx Alternatives 180 Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBM) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
